MRMarina Ramus

Marina Ramus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marina Ramus has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Empowering active surveillance of Carbapenem-resistant Enterobacterales: Insights from one year of genomic surveillance

    by Greta Petazzoni, Stefano Gaiarsa, Irene Mileto, Angela Kuka, Marta Corbella, Cristina Merla, Antonio Piralla, Marina Ramus, Aurora Piazza, Vittoria Mattioni Marchetti, et al.


  • Human Cytomegalovirus Virion‐Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients

    by Federica Giardina, Stefania Paolucci, Dalila Mele, Omar Mura, Marina Ramus, José Camilla Sammartino, Piera D'Angelo, Antonino Maria Guglielmo Pitrolo, Giulia Campanini, Eleonora Francesca Pattonieri, et al.

    Human Cytomegalovirus (HCMV) transcripts (including UL21.5 mRNA) have been found to be packaged in virions, and their detection in plasma may indicate the presence of infectious viral particles. The objective of this study was to verify whether UL21.5 mRNA detected in the plasma was indeed encapsulated in viral particles, representing an indirect marker of active replication. To distinguish between virion‐packaged and free‐floating RNA, plasma samples from 22 immunocompromised patients were tested before and after ribonuclease (RNAse) digestion. UL21.5 mRNA was detected 1–2 weeks before preemptive therapy administration in 20 episodes (from 18 patients) of clinically significant DNAemia, while it was undetectable in three of the four patients with transient, self‐resolving DNAemia. After RNAse digestion, UL21.5 mRNA was still detectable, with a median reduction of 0.1 (IQR: 0–0.3) Log10. Concentrations of UL21.5 mRNA in plasma correlated significantly with HCMV DNA in whole blood or plasma (R = 0.67), and 75% of samples positive for UL21.5 mRNA had HCMV DNA concentrations above 104 copies/mL blood or 103 copies/mL plasma. Moreover, UL21.5 mRNA was positive in patients who developed HCMV infection resistant to letermovir or maribavir, whereas it was undetectable in the plasma of patients with transient self‐resolving DNAemia blips during letermovir prophylaxis (not associated with drug‐resistance). HCMV UL21.5 mRNA in plasma is virion‐associated and represents a marker for productive HCMV infection. The determination of UL21.5 mRNA could improve current strategies for the management of HCMV infection in immunocompromised patients.


  • Open Access

    Rapid spread of a novel NDM-producing clone of Klebsiella pneumoniae CC147, Northern Italy, February to August 2023

    by Irene Mileto, Greta Petazzoni, Marta Corbella, Stefano Gaiarsa, Cristina Merla, Angela Kuka, Marina Ramus, Cristina Terulla, Micaela Brandolini, Antonio Piralla, et al.

    New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae (Kp) ST147 caused a large multi-hospital outbreak in Italy from 2018 to 2021. We describe a new ST6668 NDM-producing Kp clone, belonging to CC147, which rapidly spread across hospitals in the Pavia province (Northern Italy) from February to August 2023. Genomic analyses revealed that ST6668 is different from ST147 and fast evolving. As shown here, genomic surveillance programmes are useful for tracking the spread of new clones with reduced susceptibility to most antibiotics.